INDGN

Bulk and Block deals for Indegene Ltd. on NSE and BSE

Founded in 1998, Indegene offers solutions for biopharmaceutical, biotech, and medical devices companies, facilitating product development, market launch, and sales lifecycle management. The company has made significant strides in expanding its client base and enhancing its technological capabilities, marked by the launch of its Cortex GenAI platform tailored for the life sciences industry. Market cap : 14174 Cr. Segment: Healthcare CMP: 590 PE: 34 Peer P/E : 44.64 5 Years CAGR 67.9% 3 Years ROC 24.3% The most recent Bulk deal for Indegene Ltd. happened on June 4, 2025 on NSE. 1,827,856 shares were traded at an average price of Rs 591.00. CA Dawn Investments, a subsidiary of US-based Carlyle, is poised to sell 10.2 per cent stake in Indegene Ltd on Wednesday, a digital-first life sciences company, through block deals valued at approximately Rs 1,420 crore ($166 million). This transaction, as per sources, involves the sale of up to 2,44,75,403 shares at a floor price of Rs 580 each, marking a 6.41 per cent discount to the Tuesday's closing price of Rs 619.70 on BSE. Kotak and IIFL are the brokers managing this deal. Chairman and CEO of Indegene, stated, "We sustained our profitable growth momentum in Q4FY25, clocking revenue growth of 4.9 per cent QoQ, Confident by recent deal wins from the last two quarters." Indegene aims to continue this growth trajectory into FY26, strengthened by recent successes. Indegene Ltd recently reported a net profit of Rs 1,176 crore for the March quarter, an increase from Rs 948 crore in the same quarter the previous year. The company also recorded revenue from operations of Rs 7,556 crore, up from Rs 6,730 crore year-on-year, with an Ebitda margin of 20.2 per cent compared to 21.9 per cent previously. Strong Support at 580 to 600 Strong Resistance at 650 to 680